$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000117867019000005 Filed on October 31, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2018 Q3
Revenue	$71.68M	$70.06M	$2.069M
YoY Change	240.8%	3286.23%	-87.9%
Cost Of Revenue	$12.20M	$5.213M	$137.0K
YoY Change	617.65%	3705.11%
Gross Profit	$59.50M	$64.85M	$1.932M
YoY Change	206.7%	3256.52%
Gross Profit Margin	83.01%	92.56%	93.38%
Selling, General & Admin	$156.3M	$120.4M	$116.5M
YoY Change	43.79%	3.27%	144.84%
% of Gross Profit	262.69%	185.59%	6032.35%
Research & Development	$201.3M	$160.8M	$139.9M
YoY Change	53.66%	14.9%	46.85%
% of Gross Profit	338.32%	247.96%	7243.53%
Depreciation & Amortization	$5.500M	-$10.30M	$3.300M
YoY Change	-339.13%	-412.12%	-8.33%
% of Gross Profit	9.24%	-15.88%	170.81%
Operating Expenses	$357.6M	$281.1M	$256.5M
YoY Change	49.19%	9.61%	79.49%
Operating Profit	-$298.1M	-$216.3M	-$254.6M
YoY Change	35.32%	-15.03%	102.35%
Interest Expense	$7.300M	$0.00	$6.800M
YoY Change	-31.13%	-100.0%	106.06%
% of Operating Profit
Other Income/Expense, Net	$14.20M	$7.370M	$9.721M
YoY Change	-1192.31%	-24.18%	239.54%
Pretax Income	-$276.6M	-$208.9M	-$244.8M
YoY Change	31.03%	-14.67%	99.16%
Income Tax	-$400.0K	-$394.0K	$445.0K
% Of Pretax Income
Net Earnings	-$276.2M	-$208.5M	-$245.3M
YoY Change	30.62%	-14.98%	99.52%
Net Earnings / Revenue	-385.3%	-297.65%	-11855.1%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.470M	-$1.918M	-$2.434M
COMMON SHARES
Basic Shares Outstanding	111.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.522B	$1.721B	$1.222B
YoY Change	40.56%	40.86%	28.84%
Cash & Equivalents	$547.2M	$923.3M	$316.6M
Short-Term Investments	$975.0M	$797.8M	$905.2M
Other Short-Term Assets	$80.30M	$73.50M	$90.80M
YoY Change	8.96%	-19.05%	198.68%
Inventory	$56.35M	$54.56M	$11.08M
Prepaid Expenses
Receivables	$43.01M	$48.11M	$3.362M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.716B	$1.897B	$1.342B
YoY Change	42.91%	41.36%	35.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$425.2M	$396.5M	$272.7M
YoY Change	32.6%	45.38%	68.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.07M	$9.632M	$60.90M
YoY Change	109.54%	-84.18%	4040.04%
Total Long-Term Assets	$679.3M	$644.4M	$333.6M
YoY Change	81.57%	93.16%	-8.59%
TOTAL ASSETS
Total Short-Term Assets	$1.716B	$1.897B	$1.342B
Total Long-Term Assets	$679.3M	$644.4M	$333.6M
Total Assets	$2.395B	$2.542B	$1.676B
YoY Change	52.09%	51.68%	23.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$49.88M	$39.39M	$21.80M
YoY Change	-16.45%	80.7%	135.96%
Accrued Expenses	$197.2M	$177.9M	$93.60M
YoY Change	74.95%	90.12%	82.6%
Deferred Revenue	$77.82M	$107.4M	$3.444M
YoY Change	2126.0%	3017.28%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$352.6M	$352.9M	$121.5M
YoY Change	96.44%	190.42%	20.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$30.00M
YoY Change	-100.0%	-100.0%	-80.0%
Other Long-Term Liabilities	$9.330M	$9.036M	$46.00M
YoY Change	87.92%	-80.36%	1518.58%
Total Long-Term Liabilities	$9.330M	$9.036M	$76.00M
YoY Change	87.92%	-88.11%	2574.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$352.6M	$352.9M	$121.5M
Total Long-Term Liabilities	$9.330M	$9.036M	$76.00M
Total Liabilities	$956.4M	$934.5M	$197.5M
YoY Change	250.55%	373.18%	-34.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.727B	-$3.451B
YoY Change	31.19%
Common Stock	$5.202B	$5.092B
YoY Change	24.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.439B	$1.607B	$1.478B
YoY Change
Total Liabilities & Shareholders Equity	$2.395B	$2.542B	$1.676B
YoY Change	52.09%	51.68%	23.37%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2018 Q3
OPERATING ACTIVITIES
Net Income	-$276.2M	-$208.5M	-$245.3M
YoY Change	30.62%	-14.98%	99.52%
Depreciation, Depletion And Amortization	$5.500M	-$10.30M	$3.300M
YoY Change	-339.13%	-412.12%	-8.33%
Cash From Operating Activities	-$196.0M	-$182.6M	-$153.8M
YoY Change	30.32%	18.73%	56.46%
INVESTING ACTIVITIES
Capital Expenditures	-$38.80M	-$36.10M	-$45.40M
YoY Change	3.47%	-20.48%	76.65%
Acquisitions
YoY Change
Other Investing Activities	-$182.0M	$26.00M	$141.6M
YoY Change	-163.55%	-81.64%	-227.0%
Cash From Investing Activities	-$220.9M	-$10.00M	$96.20M
YoY Change	-188.75%	-110.4%	-170.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	40.40M	-20.70M	13.00M
YoY Change	648.15%	-259.23%	-55.02%
NET CHANGE
Cash From Operating Activities	-196.0M	-182.6M	-153.8M
Cash From Investing Activities	-220.9M	-10.00M	96.20M
Cash From Financing Activities	40.40M	-20.70M	13.00M
Net Change In Cash	-376.5M	-213.3M	-44.60M
YoY Change	-462.37%	378.25%	-78.41%
FREE CASH FLOW
Cash From Operating Activities	-$196.0M	-$182.6M	-$153.8M
Capital Expenditures	-$38.80M	-$36.10M	-$45.40M
Free Cash Flow	-$157.2M	-$146.5M	-$108.4M
YoY Change	39.24%	35.15%	49.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
	alny	Impairment Of Marketable Debt Securities ImpairmentOfMarketableDebtSecurities	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36407
	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0602661
	dei	Entity Address Address Line1 EntityAddressAddressLine1	675 West Kendall Street,
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Henri A. Termeer Square
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	City Area Code CityAreaCode	617
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	551-8200
	dei	Local Phone Number LocalPhoneNumber	551-8200
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	ALNY
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	111489744	shares
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	923304000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	420146000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	797754000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	662803000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48109000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18760000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	54562000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	24068000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	73536000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	74919000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	1897265000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	1200696000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	396456000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	320658000	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	223444000	USD
CY2019Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	14825000	USD
CY2018Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	44825000	USD
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9632000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8623000	USD
CY2019Q3	us-gaap	Assets Assets	2541622000	USD
CY2018Q4	us-gaap	Assets Assets	1574802000	USD
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	39392000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	59708000	USD
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	177948000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	112719000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	28165000	USD
CY2019Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	3571000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	107359000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3496000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	352864000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	179494000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	276456000	USD
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	57920000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	296179000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	458000	USD
CY2019Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2018Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	30000000	USD
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9036000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4965000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	934535000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	272837000	USD
CY2019Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111325000	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111325000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101177000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101177000	shares
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	1113000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1011000	USD
CY2019Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	5091248000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	4175139000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-34371000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2541622000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33213000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3450903000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2840972000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1607087000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1301965000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1574802000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	70061000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2069000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148069000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53875000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5213000	USD
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	137000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12886000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	137000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	160796000	USD
CY2018Q3	us-gaap	Investment Income Net InvestmentIncomeNet	6796000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-641358000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-594317000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	139945000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	453813000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	374384000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	120351000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	116545000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	322728000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	273671000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	286360000	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	256627000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	789427000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	648192000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-216299000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-254558000	USD
CY2019Q3	us-gaap	Investment Income Net InvestmentIncomeNet	9889000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2929000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5468000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7370000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	26195000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	18691000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2519000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2925000	USD
CY2019Q3	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	0	USD
CY2018Q3	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	0	USD
	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	9422000	USD
	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	0	USD
CY2019Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2018Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	20564000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9721000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32688000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	44723000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-208929000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1261000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	462000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-208535000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-244837000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-608670000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-549594000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-394000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	445000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-245282000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-609931000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-550056000	USD
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.92
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.43
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.63
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.48
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	108701000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	100783000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	108427000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	100430000	shares
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-208535000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-245282000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-609931000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-550056000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	415000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	772000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1041000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1439000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2281000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-71000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	4211000	USD
	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax	0	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-207075000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-244867000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-611089000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-549015000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1301965000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11409000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	-58000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	784000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381900000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32541000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	360000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-181915000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1546986000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6182000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	4022000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1089000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	390577000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30798000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2978000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-219481000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	1757195000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9300000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1002000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	46665000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1460000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-208535000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	1607087000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	1766431000	USD
CY2018Q1	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	68210000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41890000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	-123000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	1754805000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	568000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19463000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-420000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-141214000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2561000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3124000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	829000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21997000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1046000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-163560000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	1620802000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13497000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	-545000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	820000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	88412000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	1478119000	USD
	us-gaap	Profit Loss ProfitLoss	-609931000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	415000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-245282000	USD
	us-gaap	Profit Loss ProfitLoss	-550056000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	11733000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	3612000	USD
	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	9422000	USD
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	5822000	USD
	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	27873000	USD
	alny	Amortization And Interest Accretion Related To Operating Leases AmortizationAndInterestAccretionRelatedToOperatingLeases	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	108644000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	129779000	USD
	alny	Non Cash Gain On Litigation Settlement NonCashGainOnLitigationSettlement	0	USD
	alny	Non Cash Gain On Litigation Settlement NonCashGainOnLitigationSettlement	10000000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	3268000	USD
	alny	Change In Fair Value Of Liability Obligation ChangeInFairValueOfLiabilityObligation	0	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-4415000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-2163000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	29717000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30640000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-29064000	USD
	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-11597000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	28095000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10354000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13662000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	34125000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3719000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-650000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	36348000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	25242000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	399584000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11503000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82447000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-412159000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	101351000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	400000000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1445632000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	992385000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	89374000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	0	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	14825000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	30000000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1320156000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1120565000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-196827000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23981000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	30942000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	60092000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	30000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	381900000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	782842000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60092000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-449000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	503119000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-328086000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	422631000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	646832000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	925750000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	318746000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18923000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	19739000	USD
	us-gaap	Nature Of Operations NatureOfOperations	NATURE OF BUSINESS<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, commercial biopharmaceutical company with a sustainable pipeline of RNAi therapeutics to address the needs of patients who have limited or inadequate treatment options. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. In August 2018, we received approval for ONPATTRO</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:9pt;font-weight:400;line-height:120%;">®</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;"> (patisiran), our first product, from the United States Food and Drug Administration and began commercializing and generating product revenues in the U.S. In October 2018, we began commercializing and generating product revenues outside of the U.S. and, as of September 30, 2019, we have launched ONPATTRO in Japan, Canada and in several countries in Europe. Regulatory filings in additional markets in Europe and elsewhere are pending or planned for the remainder of 2019 and beyond.</span>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reclassification</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:400;line-height:120%;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div>
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	290000000.0	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	230000000.0	USD
CY2019Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	28107000	USD
CY2018Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	5625000	USD
CY2019Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	158446000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3954000	USD
CY2019Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12333000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3954000	USD
CY2019Q3	alny	Increase Decrease In Transaction Price IncreaseDecreaseInTransactionPrice	18500000	USD
CY2019Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	11600000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8709000	USD
CY2019Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	42383000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	15262000	USD
CY2019Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	579000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	97000	USD
CY2019Q3	us-gaap	Inventory Net InventoryNet	54562000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	24068000	USD
CY2018Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1471546000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	395000	USD
CY2019Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	44000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1471897000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	884505000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	422000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	884084000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	674143000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	221281000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	797754000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	662803000	USD
CY2019Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1471897000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	884084000	USD
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	9282000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	27863000	USD
CY2019Q3	us-gaap	Variable Lease Cost VariableLeaseCost	3460000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	12993000	USD
CY2019Q3	us-gaap	Lease Cost LeaseCost	12742000	USD
	us-gaap	Lease Cost LeaseCost	40856000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	24800000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y4M24D
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.082
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	304621000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	8223000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	28700000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	36388000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	36510000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	35576000	USD
CY2019Q3	alny	Lessee Operating Lease Liability Payments Due Year Six LesseeOperatingLeaseLiabilityPaymentsDueYearSix	34670000	USD
CY2019Q3	alny	Lessee Operating Lease Liability Payments Due Year Seven And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearSevenAndThereafter	356208000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	536275000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	231654000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	304621000	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	28165000	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	276456000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	32228000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	34826000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	34410000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	34826000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	35270000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	390455000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	562015000	USD
CY2019Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5000000	shares
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	77.50
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381900000	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5600000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46009000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	87954000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	108644000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	129779000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	923304000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	316608000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14343000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12692000	shares
CY2019Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	4000	USD
CY2018Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2019Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2442000	USD
CY2018Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2138000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	925750000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	318746000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-1642000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-484000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1158000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-590000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-1631000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1041000	USD

Files In Submission

Name	View Source	Status
0001178670-19-000005-index-headers.html	Edgar Link	pending
0001178670-19-000005-index.html	Edgar Link	pending
0001178670-19-000005.txt	Edgar Link	pending
0001178670-19-000005-xbrl.zip	Edgar Link	pending
alny-20190930.htm	Edgar Link	pending
alny-20190930.xsd	Edgar Link	pending
alny-20190930_cal.xml	Edgar Link	unprocessable
alny-20190930_def.xml	Edgar Link	unprocessable
alny-20190930_g1.jpg	Edgar Link	pending
alny-20190930_htm.xml	Edgar Link	completed
alny-20190930_lab.xml	Edgar Link	unprocessable
alny-20190930_pre.xml	Edgar Link	unprocessable
alnyq3201910-qex311.htm	Edgar Link	pending
alnyq3201910-qex312.htm	Edgar Link	pending
alnyq3201910-qex321.htm	Edgar Link	pending
alnyq3201910-qex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2019 Q4 Form 10-Q Financial Statement

#000117867019000005 Filed on October 31, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2019 Q4 Form 10-Q Financial Statement

#000117867019000005 Filed on October 31, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny